162 related articles for article (PubMed ID: 15367418)
21. Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Folprecht G; Köhne CH; Lutz MP
Cancer Treat Res; 2007; 134():425-40. PubMed ID: 17633071
[No Abstract] [Full Text] [Related]
22. Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery.
Pérez-Ruixo C; Valenzuela B; Peris JE; Bretcha-Boix P; Escudero-Ortiz V; Farré-Alegre J; Pérez-Ruixo JJ
Cancer Chemother Pharmacol; 2013 Mar; 71(3):693-704. PubMed ID: 23274396
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis.
Elias DM; Sideris L
Surg Oncol Clin N Am; 2003 Jul; 12(3):755-69, xiv. PubMed ID: 14567029
[TBL] [Abstract][Full Text] [Related]
24. Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
Cals L; Rixe O; François E; Favre R; Merad L; Deplanque G; Laadem A; Juin P; Bereder JM; Bernardini D; Herait P
Ann Oncol; 2004 Jul; 15(7):1018-24. PubMed ID: 15205194
[TBL] [Abstract][Full Text] [Related]
25. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.
Elias D; Lefevre JH; Chevalier J; Brouquet A; Marchal F; Classe JM; Ferron G; Guilloit JM; Meeus P; Goéré D; Bonastre J
J Clin Oncol; 2009 Feb; 27(5):681-5. PubMed ID: 19103728
[TBL] [Abstract][Full Text] [Related]
26. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
[TBL] [Abstract][Full Text] [Related]
27. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis.
Cashin PH; Ehrsson H; Wallin I; Nygren P; Mahteme H
Eur J Clin Pharmacol; 2013 Mar; 69(3):533-40. PubMed ID: 22983312
[TBL] [Abstract][Full Text] [Related]
29. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies.
Jacquet P; Averbach A; Stephens AD; Stuart OA; Chang D; Sugarbaker PH
Oncology; 1998; 55(2):130-8. PubMed ID: 9499187
[TBL] [Abstract][Full Text] [Related]
30. Results of oxaliplatin-based hyperthermic intraperitoneal chemotherapy in recurrent ovarian granulosa cell tumors.
Gouy S; Uzan C; Pautier P; Lhomme C; Duvillard P; Morice P
Eur J Obstet Gynecol Reprod Biol; 2013 Oct; 170(2):464-7. PubMed ID: 23915762
[TBL] [Abstract][Full Text] [Related]
31. Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients.
Gil-Delgado MA; Bastian G; Guinet F; Spano JP; Taillibert S; Rocher MA; Castaing D; Adam R; Urien S; Bismuth H; Khayat D
Am J Clin Oncol; 2004 Jun; 27(3):294-8. PubMed ID: 15170151
[TBL] [Abstract][Full Text] [Related]
32. Rationale supporting the use of vasoconstrictors for intraperitoneal chemotherapy with platinum derivatives.
Chauffert B; Favoulet P; Polycarpe E; Duvillard C; Beltramo JL; Bichat F; Rat P; Genne P; Benoit L
Surg Oncol Clin N Am; 2003 Jul; 12(3):835-48. PubMed ID: 14567035
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Stathopoulos GP; Rigatos SK; Stathopoulos JG; Xynotroulas JP; Dimou E
Am J Clin Oncol; 2005 Dec; 28(6):565-9. PubMed ID: 16317265
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal origin.
Rietveld PCS; Sassen SDT; Guchelaar NAD; van Eerden RAG; de Boer NL; van den Heuvel TBM; Burger JWA; Mathijssen RHJ; Koch BCP; Koolen SLW
CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):1006-1016. PubMed ID: 38634204
[TBL] [Abstract][Full Text] [Related]
35. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia.
Chalret du Rieu Q; White-Koning M; Picaud L; Lochon I; Marsili S; Gladieff L; Chatelut E; Ferron G
Cancer Chemother Pharmacol; 2014 Sep; 74(3):571-82. PubMed ID: 25053386
[TBL] [Abstract][Full Text] [Related]
37. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
38. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Mazard T; Ychou M; Thezenas S; Poujol S; Pinguet F; Thirion A; Bleuse JP; Portales F; Samalin E; Assenat E
Cancer Chemother Pharmacol; 2012 Mar; 69(3):807-14. PubMed ID: 22037922
[TBL] [Abstract][Full Text] [Related]
39. Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
Sheikh HY; Valle JW; Palmer K; Sjursen A; Craven O; Wilson G; Swindell R; Saunders MP
Br J Cancer; 2007 Jan; 96(1):38-43. PubMed ID: 17213824
[TBL] [Abstract][Full Text] [Related]
40. A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers.
Stewart JH; Shen P; Russell G; Fenstermaker J; McWilliams L; Coldrun FM; Levine KE; Jones BT; Levine EA
Ann Surg Oncol; 2008 Aug; 15(8):2137-45. PubMed ID: 18493824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
